Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | RAF1 | P04049 | 10/20 | 0.35 |
| ▸ | BRAF | P15056 | 10/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208729 | 1.00 | RORC (0.36) | RORCRAF1BRAFTNFABL1 | |
| SCHEMBL1211239 | 1.00 | RORC (0.36) | RORCRAF1BRAFTNFABL1 | |
| SCHEMBL14781427 | 0.82 | TRPV1 (0.48) | NPC1RAB9ACNR1CNR2 | |
| SCHEMBL1211511 | 0.82 | TRPV1 (0.48) | NPC1RAB9ACNR1CNR2 | |
| SCHEMBL909795 | 0.78 | GHSR (0.39) | RAF1BRAFNPC1RAB9A | |
| SCHEMBL537526 | 0.78 | GHSR (0.39) | RAF1BRAFNPC1RAB9A | |
| SCHEMBL1207921 | 0.77 | TRPV1 (0.37) | RORCRAF1BRAF | |
| SCHEMBL2054552 | 0.77 | TRPV1 (0.37) | RORCRAF1BRAF | |
| SCHEMBL1208009 | 0.77 | TRPV1 (0.37) | RORCRAF1BRAF | |
| SCHEMBL1211712 | 0.74 | TRPV1 (0.53) | RORCNPC1RAB9APDE2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163901-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028465-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | RORC 2653/4885RAF1 1274/4885BRAF 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.